Rankless | Maria Khouri

Countries citing papers authored by Maria Khouri

Since Specialization

Citations

This map shows the geographic impact of Maria Khouri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Khouri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Khouri more than expected).

Fields of papers citing papers by Maria Khouri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Khouri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Khouri. The network helps show where Maria Khouri may publish in the future.

Co-authorship network of co-authors of Maria Khouri

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Khouri. A scholar is included among the top collaborators of Maria Khouri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Khouri. Maria Khouri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations 2025 ·Cancer ·Maria Khouri,Bofei Wang,(unknown),(unknown),(unknown),Lloyd Hutchinson,(unknown),Muthalagu Ramanathan,Jonathan M. Gerber,Jan Černý,Shyam A. Patel	1
2	Hyper‐CVAD plus ofatumumab versus hyper‐CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis 2021 ·Cancer ·Koji Sasaki,Hagop M. Kantarjian,Kiyomi Morita,Nicholas J. Short,Marina Konopleva,Nitin Jain,Farhad Ravandi,Guillermo Garcia‐Manero,Sa Wang,Joseph D. Khoury,Jeffrey L. Jorgensen,Richard E. Champlin,Issa F. Khouri,Partow Kebriaei,(unknown),Maria Khouri,Rebecca Garris,Koichi Takahashi,Susan O’Brien,Elias Jabbour	16
3	Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors 2020 ·Blood ·Koji Sasaki,Elias Jabbour,Ghayas C. Issa,Guillermo Garcia‐Manero,Tapan M. Kadia,William G. Wierda,Musa Yılmaz,Courtney D. DiNardo,Jeffrey Skinner,Maria Khouri,Naveen Pemmaraju,(unknown),Sherry Pierce,Jörge E. Cortes,Hagop M. Kantarjian	4
4	Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes 2019 ·Clinical Cancer Research ·Gheath Alatrash,Na Qiao,(unknown),(unknown),(unknown),Pariya Sukhumalchandra,Anne V. Philips,Haven R. Garber,(unknown),Lisa S. St. John,Maria Khouri,Hiep Khong,Karen Clise-Dwyer,Leonard P. Miller,(unknown),Willem W. Overwijk,Jeffrey J. Molldrem,Qing Ma,Elizabeth J. Shpall,Elizabeth A. Mittendorf	21
5	Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience 2018 ·Blood ·Mansour Alfayez,Hagop M. Kantarjian,Nicholas J. Short,Rita Assi,Maria Khouri,Farhad Ravandi,Shilpa Paul,Caitlin R. Rausch,(unknown),Gautam Borthakur,Courtney D. DiNardo,Tapan M. Kadia,Naval Daver,Guillermo Garcia‐Manero,Kiran Naqvi,Prithviraj Bose,Susan O’Brien,Jörge E. Cortes,Elias Jabbour	11
6	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage 2018 ·Cancer ·Elias Jabbour,Koji Sasaki,Farhad Ravandi,Xuelin Huang,Nicholas J. Short,Maria Khouri,Partow Kebriaei,Jan A. Burger,Joseph D. Khoury,Jeffrey L. Jorgensen,Nitin Jain,Marina Konopleva,Guillermo Garcia‐Manero,Tapan M. Kadia,Jörge E. Cortes,Jovitta Jacob,Kathryn Montalbano,Rebecca Garris,Susan O’Brien,Hagop M. Kantarjian	76
7	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis 2018 ·Blood ·Koji Sasaki,Hagop M. Kantarjian,Nicholas J. Short,Farhad Ravandi,Maria Khouri,Guillermo Garcia‐Manero,Naval Daver,Tapan M. Kadia,Marina Konopleva,Nitin Jain,Ghayas C. Issa,Jovitta Jacob,Rebecca Garris,Musa Yılmaz,Philip A. Thompson,(unknown),Naveen Pemmaraju,Jörge E. Cortes,Susan O’Brien,Elias Jabbour	2
8	A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results. 2018 ·Journal of Clinical Oncology ·Abdul Hamid Bazarbachi,Musa Yılmaz,Farhad Ravandi,Deborah A. Thomas,Maria Khouri,Guillermo Garcia‐Manero,Rebecca Garris,Jörge E. Cortes,Nicholas J. Short,Koji Sasaki,Ghayas C. Issa,Paul Koller,Tapan M. Kadia,Srđan Verstovšek,Naval Daver,Nitin Jain,Marina Konopleva,Susan O’Brien,Elias Jabbour,Hagop M. Kantarjian	9
9	Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia 2018 ·Blood ·(unknown),Hagop M. Kantarjian,Nicholas J. Short,Farhad Ravandi,Koji Sasaki,Guillermo Garcia‐Manero,Guillermo Montalban‐Bravo,Jörge E. Cortes,Christopher B. Benton,Ghayas C. Issa,Maria Khouri,(unknown),Susan O’Brien,Elias Jabbour	6
10	Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen 2018 ·Blood ·Caitlin R. Rausch,Shilpa Paul,Hagop M. Kantarjian,Farhad Ravandi,Nicholas J. Short,Koji Sasaki,Maria Khouri,Jovitta Jacob,Kathryn Montalbano,Philip A. Thompson,Nitin Jain,Musa Yılmaz,Kiran Naqvi,Maro Ohanian,(unknown),Zeev Estrov,Susan O’Brien,Elias Jabbour	1
11	Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease 2018 ·Blood ·(unknown),Hagop M. Kantarjian,Nicholas J. Short,Maria Khouri,Koichi Takahashi,Maro Ohanian,Gautam Borthakur,Marina Konopleva,Naval Daver,Zeev Estrov,Yesid Alvarado,Nitin Jain,Farhad Ravandi,Guillermo Garcia‐Manero,(unknown),(unknown),Susan O’Brien,Elias Jabbour	2
12	Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI) 2018 ·Blood ·Elias Jabbour,Koji Sasaki,Farhad Ravandi,Nicholas J. Short,Guillermo Garcia‐Manero,Naval Daver,Tapan M. Kadia,Marina Konopleva,Nitin Jain,Ghayas C. Issa,Zeev Estrov,Rebecca Garris,Maria Khouri,(unknown),Naveen Pemmaraju,Jörge E. Cortes,Susan O’Brien,Hagop M. Kantarjian	1
13	Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation 2017 ·Biology of Blood and Marrow Transplantation ·Maria Khouri,Elias Jabbour,Alison Gulbis,Francesco Turturro,Celina Ledesma,Martin Körbling,Barry I. Samuels,Sairah Ahmed,Amin M. Alousi,Stefan O. Ciurea,David Marín,Krina K. Patel,Uday Popat,Carlos E. Bueso‐Ramos,Roland L. Bassett,Issa F. Khouri	5
14	Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+ acute lymphoblastic leukemia. 2017 ·Journal of Clinical Oncology ·Abhishek Maiti,Hagop M. Kantarjian,Farhad Ravandi,Deborah A. Thomas,Maria Khouri,Guillermo Garcia‐Manero,Rebecca Garris,Jörge E. Cortes,Nicholas J. Short,Koji Sasaki,Ghayas C. Issa,Paul Koller,(unknown),Tapan M. Kadia,Srđan Verstovšek,Naval Daver,Nitin Jain,Marina Konopleva,Susan O’Brien,Elias Jabbour	3
15	Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Abhishek Maiti,Hagop M. Kantarjian,Farhad Ravandi,Deborah A. Thomas,Maria Khouri,Guillermo Garcia‐Manero,Rebecca Garris,Jörge E. Cortes,Nicholas J. Short,Koji Sasaki,Ghayas C. Issa,Paul Koller,(unknown),Tapan M. Kadia,Srđan Verstovšek,Naval Daver,Nitin Jain,Marina Konopleva,Susan O’Brien,Elias Jabbour	1
16	Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor 2016 ·American Journal of Hematology ·Nicholas J. Short,Hagop M. Kantarjian,Koji Sasaki,Farhad Ravandi,(unknown),C. Cameron Yin,Guillermo Garcia‐Manero,Jörge E. Cortes,Rebecca Garris,Susan O’Brien,Keyur P. Patel,Maria Khouri,Deborah A. Thomas,Nitin Jain,Tapan M. Kadia,Naval Daver,Christopher B. Benton,Ghayas C. Issa,Marina Konopleva,Elias Jabbour	33
17	Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL). 2016 ·Journal of Clinical Oncology ·Ghayas C. Issa,Hagop M. Kantarjian,Farhad Ravandi,Deborah A. Thomas,Maria Khouri,Guillermo Garcia‐Manero,Rebecca Garris,Jörge E. Cortes,Nicholas J. Short,Koji Sasaki,(unknown),Tapan M. Kadia,Srđan Verstovšek,Naval Daver,Nitin Jain,Marina Konopleva,Susan O’Brien,Elias Jabbour	1
18	Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin 2015 ·Blood ·Jad Chahoud,Hagop M. Kantarjian,Guillermo Garcia‐Manero,Koji Sasaki,Tapan M. Kadia,Jörge E. Cortes,Maria Khouri,Farhad Ravandi,(unknown),Alessandra Ferrajoli,Jovitta Jacob,Naveen Pemmaraju,Naval Daver,Rebecca Garris,Elias Jabbour	2
19	Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) 2015 ·Blood ·Koji Sasaki,Hagop M. Kantarjian,Susan O’Brien,Deborah A. Thomas,Farhad Ravandi,Guillermo Garcia‐Manero,Tapan M. Kadia,Nitin Jain,Marina Konopleva,Zeev Estrov,Koichi Takahashi,Maria Khouri,Jovitta Jacob,Rebecca Garris,Jörge E. Cortes,Elias Jabbour	11
20	Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL) 2015 ·Blood ·Koji Sasaki,Paul Koller,Hagop M. Kantarjian,Deborah A. Thomas,Maria Khouri,Guillermo Garcia‐Manero,Rebecca Garris,Jörge E. Cortes,(unknown),Jad Chahoud,Tapan M. Kadia,Farhad Ravandi,Srđan Verstovšek,Naval Daver,Nitin Jain,Marina Konopleva,Susan O’Brien,Elias Jabbour	11

About Maria Khouri

Maria Khouri is a scholar working on Genetics, Hematology and Public Health, Environmental and Occupational Health, having authored 22 papers that have together received 233 indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (18 papers), Chronic Lymphocytic Leukemia Research (10 papers) and CAR-T cell therapy research (7 papers). The work is most often cited by research in Hematology (102 citations), Public Health, Environmental and Occupational Health (170 citations) and Oncology (143 citations). Maria Khouri has collaborated with scholars based in United States. Frequent co-authors include Farhad Ravandi, Guillermo Garcia‐Manero, Elias Jabbour, Hagop M. Kantarjian, Nitin Jain, Marina Konopleva, Koji Sasaki, Jörge E. Cortes, Rebecca Garris and Tapan M. Kadia. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Maria Khouri

In The Last Decade